DK1210113T3 - Kombinerede vaccinepræparater - Google Patents

Kombinerede vaccinepræparater

Info

Publication number: DK1210113T3
Authority: DK; Denmark
Prior art keywords: combined vaccine; vaccine preparations; preparations; combined; vaccine
Prior art date: 1999-09-07

Application number

DK00967654T

Other languages

English (en)

Inventor

Martine Wettendorff

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-07

Filing date

2000-09-07

Publication date

2006-07-03

2000-09-07 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2006-07-03 Application granted granted Critical

2006-07-03 Publication of DK1210113T3 publication Critical patent/DK1210113T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09C—RECLAMATION OF CONTAMINATED SOIL
- B09C1/00—Reclamation of contaminated soil
- E—FIXED CONSTRUCTIONS
- E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
- E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
- E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
- E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Soil Sciences (AREA)
Molecular Biology (AREA)
Structural Engineering (AREA)
Environmental & Geological Engineering (AREA)
Oncology (AREA)
Paleontology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Agronomy & Crop Science (AREA)
Biotechnology (AREA)
General Life Sciences & Earth Sciences (AREA)
Mining & Mineral Resources (AREA)
Biochemistry (AREA)
Civil Engineering (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK00967654T 1999-09-07 2000-09-07 Kombinerede vaccinepræparater DK1210113T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9921146A GB9921146D0 (en)	1999-09-07	1999-09-07	Novel composition

Publications (1)

Publication Number	Publication Date
DK1210113T3 true DK1210113T3 (da)	2006-07-03

Family

ID=10860520

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03078635T DK1410805T3 (da)	1999-09-07	2000-09-07	Vaccine mod HPV
DK00967654T DK1210113T3 (da)	1999-09-07	2000-09-07	Kombinerede vaccinepræparater

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK03078635T DK1410805T3 (da)	1999-09-07	2000-09-07	Vaccine mod HPV

Country Status (33)

Country	Link
US (3)	US6936255B1 (da)
EP (3)	EP1210113B1 (da)
JP (2)	JP4689910B2 (da)
KR (2)	KR100594668B1 (da)
CN (2)	CN100389824C (da)
AR (1)	AR025502A1 (da)
AT (2)	ATE321569T1 (da)
AU (1)	AU766494B2 (da)
BR (1)	BR0014171A (da)
CA (2)	CA2384064C (da)
CO (1)	CO5280045A1 (da)
CY (2)	CY1107457T1 (da)
CZ (2)	CZ2002843A3 (da)
DE (2)	DE60024893T2 (da)
DK (2)	DK1410805T3 (da)
ES (2)	ES2253636T3 (da)
GB (1)	GB9921146D0 (da)
GC (1)	GC0000201A (da)
HK (1)	HK1048435B (da)
HU (2)	HU228687B1 (da)
IL (3)	IL158107A0 (da)
MX (1)	MXPA02002484A (da)
MY (2)	MY142842A (da)
NO (3)	NO332800B1 (da)
NZ (2)	NZ517621A (da)
PL (2)	PL201264B1 (da)
PT (1)	PT1210113E (da)
SG (1)	SG110072A1 (da)
SI (2)	SI1210113T1 (da)
TR (1)	TR200200607T2 (da)
TW (1)	TWI258374B (da)
WO (1)	WO2001017551A2 (da)
ZA (2)	ZA200306402B (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20060029617A1 (en) *	1997-10-03	2006-02-09	Charreyre Catherine E	Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr)	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
ATE335510T1 (de)	1998-05-22	2006-09-15	Ottawa Health Research Inst	Methoden und produkte zur induzierung mukosaler immunität
CZ301212B6 (cs)	1998-10-16	2009-12-09	Smithkline Beecham Biologicals S. A.	Vakcinacní prostredek
US20050002958A1 (en) *	1999-06-29	2005-01-06	Smithkline Beecham Biologicals Sa	Vaccines
GB9921147D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
EP1243655B1 (en) *	2001-03-23	2007-02-21	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Modified HPV E6 and E7 genes and proteins useful for vaccination
GB0110431D0 (en) *	2001-04-27	2001-06-20	Glaxosmithkline Biolog Sa	Novel compounds
GB0206360D0 (en) *	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
PT1506222E (pt) †	2002-05-17	2009-06-12	Univ Cape Town	Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas
AU2003254585A1 (en)	2002-07-24	2004-02-16	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
EP1537418A2 (en)	2002-09-13	2005-06-08	Intercell AG	Method for isolating hepatitis c virus peptides
MXPA05004588A (es)	2002-10-29	2005-12-14	Coley Pharmaceutical Group Ltd	Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
WO2004053104A2 (en)	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5’ cpg nucleic acids and methods of use
JP5475939B2 (ja) *	2002-12-20	2014-04-16	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｈｐｖ−１６およびｈｐｖ−１８ｌ１ｖｌｐワクチン
SI1572233T1 (sl) *	2002-12-20	2011-07-29	Glaxosmithkline Biolog Sa	Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
US7858098B2 (en) *	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
CN100355453C (zh) *	2003-03-24	2007-12-19	英特塞尔股份公司	改进的疫苗
DE602004029657D1 (de)	2003-03-24	2010-12-02	Intercell Ag	Verbesserte impfstoffe
GB0413510D0 (en) *	2004-06-16	2004-07-21	Glaxosmithkline Biolog Sa	Vaccine
US7758866B2 (en) *	2004-06-16	2010-07-20	Glaxosmithkline Biologicals, S.A.	Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2008502633A (ja) *	2004-06-16	2008-01-31	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
US7833707B2 (en)	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EP1850871A2 (en) *	2005-02-16	2007-11-07	Novartis Vaccines and Diagnostics, Inc.	Adjuvant composition comprising aluminium phosphate and 3d-mpl
JP4182074B2 (ja)	2005-03-03	2008-11-19	ファナック株式会社	ハンド及びハンドリングロボット
EP1863529A1 (en) *	2005-03-23	2007-12-12	GlaxoSmithKline Biologicals S.A.	Novel composition
SG159529A1 (en) *	2005-04-26	2010-03-30	Glaxosmithkline Biolog Sa	Vaccine
EP1877086A2 (en) *	2005-04-26	2008-01-16	GlaxoSmithKline Biologicals SA	Vaccine
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
US7790203B2 (en) *	2005-12-13	2010-09-07	Lowder Tom R	Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
DK2371383T3 (da)	2005-12-29	2015-11-30	Boehringer Ingelheim Vetmed	Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise
EP3320919B1 (en)	2005-12-29	2020-05-27	Boehringer Ingelheim Animal Health USA Inc.	Multivalent pcv2 immunogenic compositions and methods of producing such compositions
US20090246220A1 (en)	2006-08-28	2009-10-01	Ertl Hildegund C J	Constructs for enhancing immune responses
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US8273361B2 (en)	2006-09-26	2012-09-25	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
WO2008112125A1 (en)	2007-03-09	2008-09-18	Merck & Co., Inc.	Papillomavirus vaccine compositions
WO2009001867A1 (ja) *	2007-06-26	2008-12-31	Japan Health Sciences Foundation	高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR101507822B1 (ko)	2008-06-04	2015-04-24	잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼	불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
RS53607B1 (sr) *	2008-07-31	2015-04-30	Glaxosmithkline Biologicals S.A.	Vakcina protiv hpv
CN106924728B (zh) *	2009-05-22	2021-02-05	健诺西生物科学公司	针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
LT2437753T (lt)	2009-06-05	2016-12-12	Infectious Disease Research Institute	Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
AU2009348078B2 (en) *	2009-06-19	2013-03-14	Eyegene Inc.	Vaccine for cervical cancer
PE20120563A1 (es) *	2009-06-25	2012-05-17	Glaxosmithkline Biolog Sa	Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
JP6034285B2 (ja) *	2010-05-28	2016-11-30	ゾエティス・ベルジャム・エス・アー	抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
UA112970C2 (uk) *	2010-08-05	2016-11-25	Мерк Шарп Енд Доме Корп.	Інактивований вірус вітряної віспи, спосіб його одержання і застосування
CA2808285C (en) *	2010-08-27	2016-09-06	Intervet International B.V.	Potency test for vaccine formulations
CN102008721A (zh) *	2010-11-16	2011-04-13	浙江大学	一种hpv多肽/dc混合疫苗及其制备
WO2012074881A2 (en)	2010-11-24	2012-06-07	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2012141984A1 (en)	2011-04-08	2012-10-18	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102210858B (zh) *	2011-05-18	2013-05-08	北京科兴生物制品有限公司	一种肠道病毒71型与甲型肝炎联合疫苗
WO2012177970A1 (en)	2011-06-24	2012-12-27	Merck Sharp & Dohme Corp.	Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
WO2013006569A2 (en) *	2011-07-01	2013-01-10	The Regents Of The University Of California	Herpes virus vaccine and methods of use
JP6199878B2 (ja)	2011-11-23	2017-09-20	ジェノセアバイオサイエンシーズ，インコーポレイテッド	単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
US11510875B2 (en)	2012-02-07	2022-11-29	Access To Advanced Health Institute	Adjuvant formulations comprising TLR4 agonists and methods of using the same
LT2850431T (lt)	2012-05-16	2018-06-25	Immune Design Corp.	Vakcinos, skirtos hsv-2
US9624510B2 (en)	2013-03-01	2017-04-18	The Wistar Institute	Adenoviral vectors comprising partial deletions of E3
KR102039520B1 (ko)	2013-04-18	2019-11-01	이뮨 디자인 코포레이션	암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
IL310015B1 (en)	2013-12-31	2025-10-01	Access To Advanced Health Inst	Single vial formulation
CN109804075A (zh)	2016-08-01	2019-05-24	威斯塔解剖学和生物学研究所	用于疫苗应用的复制缺陷型腺病毒载体的组合物和方法
WO2018064232A1 (en)	2016-09-28	2018-04-05	Genocea Biosciences, Inc.	Methods and compositions for treating herpes
CN107987159B (zh) *	2017-11-28	2021-06-22	上海药明生物医药有限公司	一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) *	2018-12-24	2019-02-06	Tcer Ab	Immunotherapy therapy
CN114340665A (zh)	2019-05-25	2022-04-12	传染病研究所	用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
CN110576034B (zh) *	2019-10-09	2020-06-30	北京尚华生态环保科技股份公司	一种土壤原位修复方法
CN110652980B (zh) *	2019-10-09	2020-06-30	北京尚华生态环保科技股份公司	一种土壤原位修复剂
WO2021097347A1 (en)	2019-11-15	2021-05-20	Infectious Disease Research Institute	Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) *	2020-12-25	2023-12-01	中国食品药品检定研究院	一种双价人乳头瘤病毒疫苗
CN114796479A (zh) *	2022-06-02	2022-07-29	金宇保灵生物药品有限公司	一种畜类动物疫苗用水包油包水佐剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH085804B2 (ja)	1988-04-28	1996-01-24	財団法人化学及血清療法研究所	Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) *	1991-06-26	1991-08-14	Cancer Res Campaign Tech	Papillomavirus l2 protein
DK1298211T3 (da) *	1991-07-19	2006-11-13	Univ Queensland	Polynukleotidsegment af HPV16-genom
US5618536A (en) *	1992-09-03	1997-04-08	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric papillomavirus-like particles
US5437951A (en) *	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
ES2162139T5 (es)	1993-03-23	2008-05-16	Smithkline Beecham Biologicals S.A.	Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
GB9409962D0 (en) *	1994-05-18	1994-07-06	Smithkline Beecham Biolog	Novel compounds
CA2211995A1 (en) *	1995-02-24	1996-08-29	Cantab Pharmaceuticals Research Limited	Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
CA2242200A1 (en) *	1996-01-26	1997-07-31	Innogenetics N.V.	Toxoplasma gondii antigen tg20
KR100365986B1 (ko) *	1996-02-09	2003-02-20	스미스클라인 비이참 바이오로지칼즈 에스.에이.	수두대상포진바이러스유전자63생성물에대한백신
GB9711990D0 (en) *	1997-06-11	1997-08-06	Smithkline Beecham Biolog	Vaccine
GB9717953D0 (en) *	1997-08-22	1997-10-29	Smithkline Beecham Biolog	Vaccine
CA2229955C (en) *	1998-02-20	2003-12-09	Medigene Gmbh	Papilloma virus capsomere vaccine formulations and methods of use
KR20010041629A (ko) *	1998-03-09	2001-05-25	장 스테판느	혼합 백신 조성물
US6500284B1 (en)	1998-06-10	2002-12-31	Suraltech, Inc.	Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en)	1998-09-11	1998-11-04	Smithkline Beecham Plc	New vaccine and method of use
CZ301212B6 (cs)	1998-10-16	2009-12-09	Smithkline Beecham Biologicals S. A.	Vakcinacní prostredek
PT1150712E (pt) *	1999-02-05	2008-12-22	Merck & Co Inc	Formulações para a vacina do vírus do papiloma humano
GB9921147D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition

1999
- 1999-09-07 GB GB9921146A patent/GB9921146D0/en not_active Ceased
2000
- 2000-09-05 MY MYPI20033661A patent/MY142842A/en unknown
- 2000-09-05 AR ARP000104636 patent/AR025502A1/es active IP Right Grant
- 2000-09-05 CO CO00066605A patent/CO5280045A1/es not_active Application Discontinuation
- 2000-09-05 MY MYPI20004083A patent/MY130084A/en unknown
- 2000-09-06 GC GCP2000892 patent/GC0000201A/en active
- 2000-09-07 IL IL15810700A patent/IL158107A0/xx unknown
- 2000-09-07 CN CNB008154244A patent/CN100389824C/zh not_active Expired - Fee Related
- 2000-09-07 DE DE2000624893 patent/DE60024893T2/de not_active Expired - Lifetime
- 2000-09-07 EP EP20000967654 patent/EP1210113B1/en not_active Expired - Lifetime
- 2000-09-07 DK DK03078635T patent/DK1410805T3/da active
- 2000-09-07 BR BR0014171A patent/BR0014171A/pt not_active IP Right Cessation
- 2000-09-07 ES ES03078635T patent/ES2253636T3/es not_active Expired - Lifetime
- 2000-09-07 EP EP20060075129 patent/EP1769806A3/en not_active Withdrawn
- 2000-09-07 EP EP20030078635 patent/EP1410805B1/en not_active Expired - Lifetime
- 2000-09-07 ES ES00967654T patent/ES2261243T3/es not_active Expired - Lifetime
- 2000-09-07 CZ CZ2002843A patent/CZ2002843A3/cs unknown
- 2000-09-07 ZA ZA200306402A patent/ZA200306402B/xx unknown
- 2000-09-07 JP JP2001521339A patent/JP4689910B2/ja not_active Expired - Fee Related
- 2000-09-07 KR KR1020037013500A patent/KR100594668B1/ko not_active Expired - Lifetime
- 2000-09-07 PL PL362069A patent/PL201264B1/pl unknown
- 2000-09-07 CA CA 2384064 patent/CA2384064C/en not_active Expired - Fee Related
- 2000-09-07 CA CA 2443214 patent/CA2443214C/en not_active Expired - Lifetime
- 2000-09-07 US US10/070,479 patent/US6936255B1/en not_active Expired - Fee Related
- 2000-09-07 WO PCT/EP2000/008784 patent/WO2001017551A2/en not_active Ceased
- 2000-09-07 KR KR1020027003023A patent/KR100557665B1/ko not_active Expired - Fee Related
- 2000-09-07 CN CNB2004100489635A patent/CN1325117C/zh not_active Expired - Lifetime
- 2000-09-07 SI SI200030859T patent/SI1210113T1/sl unknown
- 2000-09-07 DK DK00967654T patent/DK1210113T3/da active
- 2000-09-07 NZ NZ517621A patent/NZ517621A/en unknown
- 2000-09-07 AU AU77751/00A patent/AU766494B2/en not_active Ceased
- 2000-09-07 HK HK02108383.6A patent/HK1048435B/en not_active IP Right Cessation
- 2000-09-07 DE DE2000627029 patent/DE60027029T2/de not_active Expired - Lifetime
- 2000-09-07 HU HU0202804A patent/HU228687B1/hu not_active IP Right Cessation
- 2000-09-07 MX MXPA02002484A patent/MXPA02002484A/es active IP Right Grant
- 2000-09-07 PT PT00967654T patent/PT1210113E/pt unknown
- 2000-09-07 CZ CZ20032326A patent/CZ302811B6/cs not_active IP Right Cessation
- 2000-09-07 NZ NZ52756000A patent/NZ527560A/xx not_active IP Right Cessation
- 2000-09-07 PL PL354039A patent/PL201767B1/pl not_active IP Right Cessation
- 2000-09-07 SG SG200305672A patent/SG110072A1/en unknown
- 2000-09-07 AT AT00967654T patent/ATE321569T1/de active
- 2000-09-07 AT AT03078635T patent/ATE312624T1/de active
- 2000-09-07 SI SI200030796T patent/SI1410805T1/sl unknown
- 2000-09-07 IL IL14845600A patent/IL148456A0/xx not_active IP Right Cessation
- 2000-09-07 HU HU0303215A patent/HU229099B1/hu unknown
- 2000-09-07 TR TR200200607T patent/TR200200607T2/xx unknown
- 2000-09-19 TW TW92125370A patent/TWI258374B/zh not_active IP Right Cessation
2002
- 2002-03-05 ZA ZA200201810A patent/ZA200201810B/xx unknown
- 2002-03-06 NO NO20021116A patent/NO332800B1/no not_active IP Right Cessation
2003
- 2003-08-20 JP JP2003296403A patent/JP2004067696A/ja active Pending
- 2003-08-21 NO NO20033715A patent/NO331825B1/no not_active IP Right Cessation
- 2003-09-25 IL IL158107A patent/IL158107A/en active IP Right Grant
- 2003-12-12 US US10/734,857 patent/US7101560B2/en not_active Expired - Lifetime
2006
- 2006-02-01 CY CY061100126T patent/CY1107457T1/el unknown
- 2006-06-05 CY CY20061100713T patent/CY1106090T1/el unknown
- 2006-06-29 US US11/477,879 patent/US7220551B2/en not_active Expired - Lifetime
2012
- 2012-10-08 NO NO2012016C patent/NO2012016I1/no unknown

Also Published As

Publication number	Publication date
KR20030087081A (ko)	2003-11-12
EP1210113A2 (en)	2002-06-05
AU7775100A (en)	2001-04-10
EP1210113B1 (en)	2006-03-29
CN1325117C (zh)	2007-07-11
HUP0202804A3 (en)	2004-08-30
CN1618465A (zh)	2005-05-25
WO2001017551A3 (en)	2001-09-27
DK1410805T3 (da)	2006-04-18
HK1064958A1 (en)	2005-02-08
NZ517621A (en)	2003-09-26
DE60024893D1 (de)	2006-01-19
CN1387443A (zh)	2002-12-25
HUP0202804A2 (hu)	2002-12-28
PT1210113E (pt)	2006-07-31
US7220551B2 (en)	2007-05-22
MY130084A (en)	2007-05-31
EP1410805A1 (en)	2004-04-21
NO2012016I1 (no)	2012-10-15
HK1048435A1 (en)	2003-04-04
US6936255B1 (en)	2005-08-30
MXPA02002484A (es)	2002-08-28
DE60027029T2 (de)	2006-10-19
NO20033715L (no)	2002-04-30
CA2443214C (en)	2006-03-21
HU228687B1 (en)	2013-05-28
BR0014171A (pt)	2002-05-21
ATE312624T1 (de)	2005-12-15
HUP0303215A3 (en)	2008-04-28
GB9921146D0 (en)	1999-11-10
PL201767B1 (pl)	2009-05-29
TR200200607T2 (tr)	2002-06-21
PL201264B1 (pl)	2009-03-31
IL158107A (en)	2008-11-03
ES2261243T3 (es)	2006-11-16
IL158107A0 (en)	2004-03-28
HU0303215D0 (en)	2003-11-28
CY1107457T1 (el)	2012-12-19
ZA200306402B (en)	2004-08-02
CN100389824C (zh)	2008-05-28
NO20021116L (no)	2002-04-30
CZ2002843A3 (cs)	2002-08-14
CZ302811B6 (cs)	2011-11-23
JP2003508495A (ja)	2003-03-04
NO20021116D0 (no)	2002-03-06
EP1769806A3 (en)	2007-10-24
US20040126394A1 (en)	2004-07-01
CA2384064C (en)	2010-06-01
JP4689910B2 (ja)	2011-06-01
WO2001017551A2 (en)	2001-03-15
SI1210113T1 (sl)	2006-08-31
SI1410805T1 (sl)	2006-04-30
NO332800B1 (no)	2013-01-14
PL354039A1 (en)	2003-12-15
HK1048435B (en)	2007-01-05
AR025502A1 (es)	2002-11-27
HU229099B1 (en)	2013-07-29
NO331825B1 (no)	2012-04-10
CA2384064A1 (en)	2001-03-15
CO5280045A1 (es)	2003-05-30
IL148456A0 (en)	2002-09-12
KR100557665B1 (ko)	2006-03-06
DE60024893T2 (de)	2006-07-06
ZA200201810B (en)	2004-05-26
EP1410805B1 (en)	2005-12-14
AU766494B2 (en)	2003-10-16
GC0000201A (en)	2006-03-29
CA2443214A1 (en)	2001-03-15
NO20033715D0 (no)	2003-08-21
ES2253636T3 (es)	2006-06-01
US7101560B2 (en)	2006-09-05
TW200408405A (en)	2004-06-01
KR100594668B1 (ko)	2006-06-30
NO2012016I2 (no)	2012-10-08
MY142842A (en)	2011-01-14
TWI258374B (en)	2006-07-21
KR20020027630A (ko)	2002-04-13
SG110072A1 (en)	2005-04-28
US20060280756A1 (en)	2006-12-14
DE60027029D1 (de)	2006-05-18
NZ527560A (en)	2004-12-24
ATE321569T1 (de)	2006-04-15
JP2004067696A (ja)	2004-03-04
CY1106090T1 (el)	2011-06-08
EP1769806A2 (en)	2007-04-04

Publication	Publication Date	Title
DK1210113T3 (da)	2006-07-03	Kombinerede vaccinepræparater
IS6040A (is)	2001-08-07	Valdekoxib efnablöndur
NO20014325L (no)	2001-11-14	Vaksine
NO20071303L (no)	2001-07-27	Farmasoytiske preparater
ATE490327T1 (de)	2010-12-15	Impfstoffzusammensetzung
EP1329217A4 (en)	2007-04-04	Solid preparations
EE200200038A (et)	2003-04-15	Konservitud farmatseutilised preparaadid
CY2011008I2 (el)	2014-04-09	Εμβολιο γριπης
NO20003302L (no)	2000-08-18	Vaksine
NO20031483D0 (no)	2003-04-01	Vaksine
NO20024172L (no)	2002-11-01	Vaksine
DE60002650D1 (de)	2003-06-18	Öladjuvierter Impfstoff
NO20020763L (no)	2002-04-16	Vaksine
EP1083926A4 (en)	2006-01-18	VACCINE
EE200200150A (et)	2003-04-15	Preparaat
PT1173187E (pt)	2003-10-31	Preparacoes combinadas compreendendo derivados de antraciclina
NO20015670D0 (no)	2001-11-20	Forbedrede farmasöytiske formuleringer
IS6398A (is)	2002-05-27	Lyfjablöndur
NO20005599L (no)	2001-01-08	Vaksine
DE50009295D1 (de)	2005-02-24	Vernetzerfreie zubereitungen
FR2804602B1 (fr)	2004-11-19	Preparations cosmetiques
NO20002213D0 (no)	2000-04-28	Babesia vaksine
ITMI992410A0 (it)	1999-11-18	Vaccino per hiv
SE9904109D0 (sv)	1999-11-12	Kosmetisk beredning